185 related articles for article (PubMed ID: 14687413)
21. Persistence of replicating coxsackievirus B3 in the athymic murine heart is associated with development of myocarditic lesions.
Sato S; Tsutsumi R; Burke A; Carlson G; Porro V; Seko Y; Okumura K; Kawana R; Virmani R
J Gen Virol; 1994 Nov; 75 ( Pt 11)():2911-24. PubMed ID: 7964602
[TBL] [Abstract][Full Text] [Related]
22. Dose-dependent protective effect of nicotine in a murine model of viral myocarditis induced by coxsackievirus B3.
Li-Sha G; Jing-Lin Z; Guang-Yi C; Li L; De-Pu Z; Yue-Chun L
Sci Rep; 2015 Oct; 5():15895. PubMed ID: 26507386
[TBL] [Abstract][Full Text] [Related]
23. Phyllaemblicin B inhibits Coxsackie virus B3 induced apoptosis and myocarditis.
Wang YF; Wang XY; Ren Z; Qian CW; Li YC; Kaio K; Wang QD; Zhang Y; Zheng LY; Jiang JH; Yang CR; Liu Q; Zhang YJ; Wang YF
Antiviral Res; 2009 Nov; 84(2):150-8. PubMed ID: 19699238
[TBL] [Abstract][Full Text] [Related]
24. Antiviral activity of WIN 54954 in coxsackievirus B2 carrier state infected human myocardial fibroblasts.
Heim A; Pfetzing U; Müller G; Grumbach IM
Antiviral Res; 1998 Jan; 37(1):47-56. PubMed ID: 9497072
[TBL] [Abstract][Full Text] [Related]
25. The heart-protective mechanism of Qishaowuwei formula on murine viral myocarditis induced by CVB3.
Fengqin L; Yulin W; Xiaoxin Z; Youpeng J; Yan C; Qing-qing W; Hong C; Jia S; Lei H
J Ethnopharmacol; 2010 Feb; 127(2):221-8. PubMed ID: 19932162
[TBL] [Abstract][Full Text] [Related]
26. Blocking the CD40-CD40L interaction by CD40-Ig reduces disease progress in murine myocarditis induced by CVB3.
Bo H; Zhenhu L; Lijian Z
Cardiovasc Pathol; 2010; 19(6):371-6. PubMed ID: 19914091
[TBL] [Abstract][Full Text] [Related]
27. Detection of viral RNA in experimental coxsackievirus B3 myocarditis of mice using the polymerase chain reaction.
Okada I; Matsumori A; Kyu B
Int J Exp Pathol; 1992 Dec; 73(6):721-31. PubMed ID: 1337265
[TBL] [Abstract][Full Text] [Related]
28. 5'-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA.
Kim KS; Tracy S; Tapprich W; Bailey J; Lee CK; Kim K; Barry WH; Chapman NM
J Virol; 2005 Jun; 79(11):7024-41. PubMed ID: 15890942
[TBL] [Abstract][Full Text] [Related]
29. Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3.
Seko Y
Clin Sci (Lond); 2006 Mar; 110(3):379-86. PubMed ID: 16336207
[TBL] [Abstract][Full Text] [Related]
30. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti-inflammatory effects.
Takada H; Kishimoto C; Hiraoka Y
Circulation; 1995 Sep; 92(6):1604-11. PubMed ID: 7664447
[TBL] [Abstract][Full Text] [Related]
31. Effect of prophylactically applied CpG ODN on the development of myocarditis in mice infected with Coxsackievirus B3.
Zhao T; Wu X; Song D; Fang M; Guo S; Zhang P; Wang L; Wang L; Yu Y
Int Immunopharmacol; 2012 Dec; 14(4):665-73. PubMed ID: 23063973
[TBL] [Abstract][Full Text] [Related]
32. The stem loop II within the 5' nontranslated region of clinical coxsackievirus B3 genomes determines cardiovirulence phenotype in a murine model.
Dunn JJ; Bradrick SS; Chapman NM; Tracy SM; Romero JR
J Infect Dis; 2003 May; 187(10):1552-61. PubMed ID: 12721935
[TBL] [Abstract][Full Text] [Related]
33. Role of MIP-2 in coxsackievirus B3 myocarditis.
Kishimoto C; Kawamata H; Sakai S; Shinohara H; Ochiai H
J Mol Cell Cardiol; 2000 Apr; 32(4):631-8. PubMed ID: 10756119
[TBL] [Abstract][Full Text] [Related]
34. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection.
Margolis DM; Mukherjee AL; Fletcher CV; Hogg E; Ogata-Arakaki D; Petersen T; Rusin D; Martinez A; Mellors JW
AIDS; 2007 Oct; 21(15):2025-32. PubMed ID: 17885292
[TBL] [Abstract][Full Text] [Related]
35. Diverse stage-dependent effects of glucocorticoids in a murine model of viral myocarditis.
Nakamura H; Kunitsugu I; Fukuda K; Matsuzaki M; Sano M
J Cardiol; 2013 Mar; 61(3):237-42. PubMed ID: 23415923
[TBL] [Abstract][Full Text] [Related]
36. Effect of verapamil on acute coxsackievirus B3 murine myocarditis.
Xu Y; Yang YZ; Chen HZ; Jin PY; Guo Q; Zhao WZ; Yang JH; Cai QX; Zhou YC
Chin Med J (Engl); 1992 Oct; 105(10):818-21. PubMed ID: 1337875
[TBL] [Abstract][Full Text] [Related]
37. Protective effects of 20(s)-protopanaxtriol on viral myocarditis infected by coxsackievirus B3.
Wang X; Wang Y; Ren Z; Qian C; Li Y; Wang Q; Zhang Y; Zheng L; Jiang J; Yang C; Wang D; Zhang Y; Fan J; Wang Y
Pathobiology; 2012; 79(6):285-9. PubMed ID: 22688124
[TBL] [Abstract][Full Text] [Related]
38. Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice.
Lutton CW; Gauntt CJ
J Interferon Res; 1985; 5(1):137-46. PubMed ID: 2985716
[TBL] [Abstract][Full Text] [Related]
39. Intracellular viral localization in murine coxsackievirus-B3 myocarditis. Ultrastructural study by electron microscopic in situ hybridization.
Ukimura A; Deguchi H; Kitaura Y; Fujioka S; Hirasawa M; Kawamura K; Hirai K
Am J Pathol; 1997 Jun; 150(6):2061-74. PubMed ID: 9176398
[TBL] [Abstract][Full Text] [Related]
40. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
J Pharmacol Exp Ther; 1992 Mar; 260(3):1386-91. PubMed ID: 1372051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
